Report: Brain–computer interfaces set to enter a 2026 “golden window” for large‑scale commercialization

Golden window backed by policy and industry research

A new study by the Beijing Fourth Wave Tech Think Tank (北京第四波科技智库) and the Zhongguancun Tiancheng Innovation Research Center (中关村天成创新研究中心) says brain–computer interfaces (BCIs) are approaching a “golden window” for large‑scale commercialization, with 2026 tipped as the year of scaled application. The report analyzed more than 80 Chinese BCI firms and argues that the convergence of policy support, technical breakthroughs, capital inflows and latent market demand will push the sector from lab demos into clinical and commercial deployment. BCIs were reportedly written into the government work report for the first time in 2026 and identified as a priority future industry for the 15th Five‑Year Plan period.

Clinical breakthroughs are the likely ignition point

The study finds medical applications will be the industry’s most immediate commercial drivers. It has been reported that invasive BCIs have reached a “quasi‑commercial” stage in clinical use: Naohu Technology (脑虎科技), Boruikang (博睿康) and Jieti Medical (阶梯医疗) are cited as having accumulated clinical cases, and some semi‑ or flexible‑invasive devices have entered the National Medical Products Administration’s (NMPA) green channel for innovative devices — with 2026–2027 approvals expected. It has also been reported that XinzhiDa (芯智达)’s “Beinao‑1” plan aims to complete 40 implant surgeries for spinal injury patients in 2026, and that Boruikang’s implanted hand‑movement compensation system has been granted a Class III medical device registration certificate, reportedly becoming the world’s first approved invasive BCI medical device.

Sizeable market forecasts, consolidation and geopolitical headwinds

Multiple institutes project rapid growth: one consultancy foresees a RMB 4.6 billion (46亿元) Chinese market in 2026, the China Academy of Information and Communications Technology (CAICT) estimates RMB 10–14 billion by 2030, and McKinsey projects global medical‑BCl market value of about $40 billion by 2030 and over $1.45 trillion by 2040. The report aggregates these views and forecasts China’s BCI market to exceed RMB 5 billion in 2026 and surpass RMB 15 billion by 2030. It predicts vertical consolidation across materials, devices and clinical providers, emergence of 3–5 internationally influential full‑stack leaders, and a set of niche “hidden champions.”

Geopolitics matters. The sector will likely rely on advanced chips, sensors and electrode materials that are increasingly subject to export controls and sanctions. Domestic tech giants — Huawei (华为), Xiaomi (小米), Tencent (腾讯), Baidu (百度) — and medical groups such as Mindray (迈瑞医疗) and United Imaging (联影医疗) are reportedly preparing M&A moves to fill capability gaps, but supply‑chain constraints could accelerate domestic substitution and reshape global collaboration. The report also warns of a market shake‑out: teams that offer “stories” without stable products, clinical evidence or real application scenarios risk rapid elimination as the industry normalizes.